PharmaTher Files for FDA Orphan Drug Designation for Ketamine to Treat Lou Gehrig’s Disease

CANNANNEW REPORT

TORONTO, May 25, 2021 (GLOBE NEWSWIRE) — PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage… Read More…..

Excerpt only …
READ MORE BELOW
Source : PharmaTher Files for FDA Orphan Drug Designation for Ketamine to Treat Lou Gehrig’s Disease

reposted by Cannabis News World

This site uses Akismet to reduce spam. Learn how your comment data is processed.